PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsCerebral infarction
MeSH D002544 - cerebral infarction
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D020520:Brain infarction
0 Companies
0 Drugs
Success rate
D002544: 
Cerebral infarction
37 Companies
5 Drugs
$
Success rate
D015161:Multi-infarct dementia
0 Companies
0 Drugs
Success rate
D020243:Anterior cerebral artery infarction
0 Companies
0 Drugs
Success rate
D020244:Middle cerebral artery infarction
0 Companies
0 Drugs
Success rate
D020762:Posterior cerebral artery infarction
0 Companies
0 Drugs
Success rate
D046589:Cadasil
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
MylanHeparin Heparin  2017-11-30   
SandozHeparin Heparin  2011-06-08   
Aspen GlobalHeparin Liquaemin  1982-01-01   
NovartisHeparin, Lidocaine, Dihydroergotamine Embolex  1984-11-30   
SanofiHeparin Calciparine  1982-01-01   
3MHeparin Lipo-hepin  1982-01-01   
PfizerHeparin Heparin  1982-01-01   
Eli LillyHeparin Heparin  1982-01-01   
Dr Reddys LaboratoriesHeparin Heparin  1996-06-07   
HospiraHeparin Heparin  1996-07-26   
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
100%
3/3
Phase 2
40%
4/10
Phase 3
40%
6/15
Approved: 2Overall Success rate: 16%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Aspen Global
Heparin,
Heparin sodium
Novartis
Dihydroergotamine,
Heparin,
Heparin sodium,
Lidocaine
Sanofi
Heparin,
Heparin sodium
Pfizer
Heparin,
Heparin sodium,
Antithrombin iii,
Serine
Eli Lilly
Heparin,
Heparin sodium
1
2
3
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use